Загрузка...
LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis
Blastic plasmacytoid dendritic cell (PDC) neoplasm (BPDCN) is an aggressive hematological malignancy with a poor prognosis that derives from PDCs. No consensus for optimal treatment modalities is available today and the full characterization of this leukemia is still emerging. We identified here a B...
Сохранить в:
| Опубликовано в: : | Blood |
|---|---|
| Главные авторы: | , , , , , , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society of Hematology
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5271175/ https://ncbi.nlm.nih.gov/pubmed/27702801 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-06-724807 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|